198 related articles for article (PubMed ID: 37443818)
1. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment.
Dumitru AV; Țăpoi DA; Halcu G; Munteanu O; Dumitrascu DI; Ceaușu MC; Gheorghișan-Gălățeanu AA
Cells; 2023 Jul; 12(13):. PubMed ID: 37443818
[TBL] [Abstract][Full Text] [Related]
2. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
3. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
4. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
5. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
[TBL] [Abstract][Full Text] [Related]
6. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
Kim LH; Eow GI; Peh SC; Poppema S
Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
[TBL] [Abstract][Full Text] [Related]
7. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Thomaides A; Atwell C; Ford R; Jones D; Claret FX; Medeiros LJ
Mod Pathol; 2005 Oct; 18(10):1365-70. PubMed ID: 15920551
[TBL] [Abstract][Full Text] [Related]
8. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
9. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma.
Tang H; Wei Q; Ge J; Jian W; Liu J; Zhong L; Fu B; Zhao T
Hum Pathol; 2013 Oct; 44(10):2167-72. PubMed ID: 23845468
[TBL] [Abstract][Full Text] [Related]
10. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
11. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
[TBL] [Abstract][Full Text] [Related]
12. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas.
Rodig SJ; Savage KJ; Nguyen V; Pinkus GS; Shipp MA; Aster JC; Kutok JL
Am J Surg Pathol; 2005 Feb; 29(2):196-203. PubMed ID: 15644776
[TBL] [Abstract][Full Text] [Related]
13. Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.
Zhou M; Fadlelmola FM; Cohn JB; Skinnider B; Gascoyne RD; Banerjee D
Mol Cancer; 2008 Jan; 7():12. PubMed ID: 18218123
[TBL] [Abstract][Full Text] [Related]
14. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.
Schwarting R; Behling E; Allen A; Arguello-Guerra V; Budak-Alpdogan T
Arch Pathol Lab Med; 2022 Apr; 146(4):415-432. PubMed ID: 35299246
[TBL] [Abstract][Full Text] [Related]
15. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
16. A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma.
Döring C; Hansmann ML; Agostinelli C; Piccaluga PP; Facchetti F; Pileri S; Küppers R; Newrzela S; Hartmann S
Mod Pathol; 2014 Oct; 27(10):1345-54. PubMed ID: 24633193
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.
Dürkop H; Hirsch B; Hahn C; Foss HD; Stein H
J Pathol; 2003 Jun; 200(2):229-39. PubMed ID: 12754742
[TBL] [Abstract][Full Text] [Related]
18. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
McQuaid DC; Katz SG; Xu ML
Am J Clin Pathol; 2022 Aug; 158(2):173-176. PubMed ID: 35460405
[TBL] [Abstract][Full Text] [Related]
19. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
20. CD30 induces Reed-Sternberg cell-like morphology and chromosomal instability in classic Hodgkin lymphoma cell lines.
Watanabe M; Hatsuse H; Nagao K; Nakashima M; Uchimaru K; Otsu M; Miyazaki K; Horie R
Cancer Sci; 2023 Aug; 114(8):3433-3445. PubMed ID: 37302818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
